- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Health Care Businesses
UnitedHealth to acquire Medicare insurer XLHealth
November 22, 2011
Bloomberg NewsUnitedHealth Group Inc. said it will acquire XLHealth Corp., a provider of managed care for chronically ill Medicare members.
Indianapolis-based WellPoint Inc. had been considering a possible acquisition of the company.
MorePotential Lilly drug doubles good cholesterol
November 15, 2011
Bloomberg NewsEli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck &
Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
MoreCash-strapped Arcadia seeks DailyMed buyer
November 15, 2011
Scott OlsonThe Indianapolis-based company is searching for a buyer for its once-promising DailyMed pharmacy service as it struggles to
pay $30 million in debt that comes due in April.
MorePotential Effient rival shows promise in study
November 14, 2011
Bloomberg NewsA study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could
give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
MoreLilly files suit over flea medication sales from Australia
November 11, 2011
Scott OlsonThe Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication's
trademark by reselling it to U.S. consumers online.
MoreLilly hid Zyprexa's diabetes risks, family’s lawyer argues
November 2, 2011
Bloomberg NewsEli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who
died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award
the family $40 million in compensatory damages.
MoreLilly loses British Supreme Court ruling over gene patent
November 2, 2011
Bloomberg NewsThe British Supreme Court ruled in favor of Human Genome Sciences Inc. in its dispute with Eli Lilly and Co. over the validity
of a patent for a gene sequence that could be used to treat people with immune diseases.
MoreOrtho firms pull back on doc payments
October 31, 2011
J.K. WallThe number of payments in excess of $1 million didn’t change substantially from year to year, but orthopedic companies
sharply cut their fees to surgeons who received the smallest amounts.
MoreInsurer Humana's quarterly profit climbs 13 percent
October 31, 2011
Associated PressHumana Inc. raised its 2011 earnings forecast, following the lead set by other big insurers, including competitor WellPoint
Inc.
MoreLilly wins European approval for new use of Alimta
October 28, 2011
J.K. WallIndianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales
after recent loss of patent on bestseller Zyprexa.
MoreHill-Rom sees better earnings, revenue in quarter
October 27, 2011
IBJ StaffHill-Rom Holdings Inc. posted better-than-expected earnings and revenue in its fiscal fourth quarter, the Batesville-based
hospital-bed supplier announced Wednesday.
MoreLilly diabetes drug wins approval for expanded use
October 19, 2011
Bloomberg NewsEli Lilly and Co. and Amylin Pharmaceuticals Inc.’s Byetta has received expanded approval for use with the world’s
top-selling insulin to treat Type 2 diabetes.
MoreLilly announces replacements for two retiring executives
October 11, 2011
J.K. WallBryce Carmine, president of Lilly’s bio-medicines division, and Frank Deane, president of Lilly’s global manufacturing
operations, both will retire on Dec. 31.
MoreLilly CEO says he's not interested in Pfizer animal unit
October 5, 2011
Bloomberg NewsDrugmaker Eli Lilly and Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, CEO John Lechleiter
said Wednesday.
MoreEli Lilly, Turkish firm in talks to sell drugs in 26 nations
October 3, 2011
Bloomberg NewsEli Lilly and Co., the world’s biggest maker of psychiatric drugs, is in talks with Mustafa Nevzat Ilac Sanayii AS to
sell the Turkish company’s treatments in 26 countries, said Mustafa Nevzat’s CEO.
MoreQ&A
September 26, 2011
J.K. WallDr. Ed Kowlowitz, owner and medical director of the Center for Pain Management in Indianapolis, recently
challenged a regional Medicare reimbursement policy and, surprisingly, won. He spoke with IBJ about the experience,
as well how his three-physician practice is growing even while many physician practices are selling to hospitals.
MoreLilly's Alimta get favorable opinion for new use in Europe
September 26, 2011
J.K. WallIf approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients,
generating more revenue.
MoreCarmel-based company buys medical-billing firm
September 16, 2011
Francesca JaroszZotec Partners, a fast-growing physician-billing management company based in Carmel, has acquired a family-owned medical-billing
firm with 100 employees based in Florida.
MoreFDA gets new report on Lilly diabetes drug
September 12, 2011
Associated PressDrugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly
diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.
MoreFDA deal with drugmakers raises user fees 6 percent
September 1, 2011
Bloomberg NewsDrugmakers including Eli Lilly an Co. have agreed with regulators on a 6-percent increase in review fees as part of reauthorizing
the drug-approval process through fiscal 2017.
MorePrivate firm with Medicaid deal gets state help
August 31, 2011
IBJ Staff and Associated PressOfficials with the Missouri Department of Health and Senior Services say they had to hire 13 temporary workers and shift as
many as 20 state workers from their regular jobs after withering consumer complaints against SynCare LLC of Indiana.
MoreMissouri health care advocates decry Indiana contractor
August 30, 2011
IBJ Staff and Associated PressIndianapolis-based SynCare LLC, hired to determine the eligibility of Missouri Medicaid patients for in-home care, has "been
a complete disaster from the beginning," statewide health care advocates charge.
MoreArcadia Resources to delist stock amid cash crunch
August 16, 2011
J.K. WallArcadia Resources Inc.'s share price dwindled to just 5 cents as of late Tuesday morning, following the company's announcement
that it was delisting its stock and had suffered another quarterly loss.
MoreOrthopedics company plans $27M Indiana project
August 5, 2011
Associated PressWarsaw-based DePuy Orthopaedics expects to spend $20 million on manufacturing equipment and $7 million on research and development
equipment and have it installed before 2014.
MoreEndocyte completes secondary public offering
August 3, 2011
The West Lafayette-based biotech firm raised about $66.8 million by selling nearly 6.7 million shares of company stock, priced
at $12.26 per share.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
these guys only skill was to steal from other's hard earned savings.
I voted for him last time and it WAS the LAST time. He needed to to quit running around the world on useless trips, and giving our $$ away to sports teams. I'll vote for anyone but Ballard next time. BTW...we gave $40M to the Pacers and cannot even watch the games on TV.
For the people concerned about traffic, you should know that mixed-use projects (like the one being proposed), actually allows for and encourages more people to walk and bike, thereby mitigating additional automobile traffic. If we continue to design and build suburban-type projects in the City (i.e. automobile-oriented projects), we are not offering anything different from what the suburbs offer, which means we will continue to lose jobs/people to the suburbs. The reason Broad Ripple is somewhat successful today is that people want to live in a place that offers the convenience of being able to walk/bike to restaurants, retail, nightlife, the Monon, etc. Why would you not want to support a project that is complimentary to what already makes the area desirable? The real argument with this project should be its lack-luster design and layout, not the density.
It is unfortunate that there is a perception that celebrities validate an event. The Indy 500 stands on its own, especially for those coming in from out of town. It was always so disturbing to read the gushing descriptions of Ashley Judd threaded throughout the local coverage. Very happy that era is at an end.
Good ole' Obamacare. Thanks liberals and those who didn't bother to vote.